-
公开(公告)号：US09611223B2
公开(公告)日：2017-04-04
申请号：US14917788
申请日：2014-09-11
发明人： Alan Ashworth , Christopher James Lord , Richard James Rowland Elliott , Dan Niculescu-Duvaz , Roderick Alan Porter , Rehan Aqil , Raymond John Boffey , Melanie Jayne Bayford , Stuart Firth-Clark , Anna Hopkins , Ashley Nicholas Jarvis , Trevor Robert Perrior , Philip Alan Skone , Rebekah Elisabeth Key
IPC分类号： C07D217/24 , C07D401/14 , C07D413/14 , C07D401/10 , C07D413/10 , C07D471/08 , C07C53/06 , C07C53/18 , C07D401/04 , C07D401/12 , C07D413/12 , C07D487/08 , C07F7/18
CPC分类号： C07D217/24 , C07C53/06 , C07C53/18 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D471/08 , C07D487/08 , C07F7/1804
摘要： The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.
-
2.发明授权3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use 有权3-芳基-5-取代 - 异喹啉-1-酮化合物及其治疗用途公开(公告)号：US09193689B2
公开(公告)日：2015-11-24
申请号：US14381712
申请日：2013-03-07
发明人： Alan Ashworth , Christopher James Lord , Richard James Rowland Elliot , Dan Niculescu-Duvaz , Roderick Porter , Raymond John Boffey , Melanie Jayne Bayford , Stuart Firth-Clark , Ashley Nicholas Jarvis , Trevor Robert Perrior , Rebekah Elisabeth Key
IPC分类号： C07D401/04 , A61K31/4725 , C07D217/24 , C07D401/14 , C07D217/14 , C07D217/16 , C07D401/10 , C07D401/12 , C07D405/12 , C07D487/04 , C07D487/08 , C07D487/10
CPC分类号： C07D217/24 , C07D217/14 , C07D217/16 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D487/04 , C07D487/08 , C07D487/10
摘要： The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.
摘要翻译： 本发明一般涉及治疗化合物领域。 更具体地，本发明涉及特别是抑制PARP（例如PARP1，TNKS1，TNKS2等）和/或Wnt信号传导的某些3-芳基-5-取代-2H-异喹啉-1-酮化合物。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制PARP（例如PARP1，TNKS1，TNKS2等）; 抑制Wnt信号; 治疗通过抑制PARP而改善的疾病（例如PARP1，TNKS1，TNKS2等）; 治疗通过抑制Wnt信号传导而改善的病症; 治疗癌症等增殖性疾病
-
3.发明申请3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE 有权3-氨基-5-取代的异喹啉-1-酮化合物及其治疗用途公开(公告)号：US20150099732A1
公开(公告)日：2015-04-09
申请号：US14381712
申请日：2013-03-07
发明人： Alan Ashworth , Christopher James Lord , Richard James Rowland Elliot , Dan Niculescu-Duvaz , Roderick Porter , Raymond John Boffey , Melanie Jayne Bayford , Stuart Firth-Clark , Ashley Nicholas Jarvis , Trevor Robert Perrior , Rebekah Elisabeth Key
IPC分类号： C07D217/24 , C07D401/14 , C07D487/08 , C07D401/12 , C07D487/10 , C07D405/12 , C07D401/10 , C07D401/04 , C07D487/04
CPC分类号： C07D217/24 , C07D217/14 , C07D217/16 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D487/04 , C07D487/08 , C07D487/10
摘要： The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.
摘要翻译： 本发明一般涉及治疗化合物领域。 更具体地，本发明涉及特别是抑制PARP（例如PARP1，TNKS1，TNKS2等）和/或Wnt信号传导的某些3-芳基-5-取代-2H-异喹啉-1-酮化合物。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制PARP（例如PARP1，TNKS1，TNKS2等）; 抑制Wnt信号; 治疗通过抑制PARP而改善的疾病（例如PARP1，TNKS1，TNKS2等）; 治疗通过抑制Wnt信号传导而改善的病症; 治疗癌症等增殖性疾病
-
-
搜索结果
3 条记录 (耗时 0.031 秒)
